4.6 Review

Epidemiological Interpretation of Studies Examining the Effect of Antibiotic Usage on Resistance

Journal

CLINICAL MICROBIOLOGY REVIEWS
Volume 26, Issue 2, Pages 289-307

Publisher

AMER SOC MICROBIOLOGY
DOI: 10.1128/CMR.00001-13

Keywords

-

Categories

Funding

  1. Pfizer (Europe)
  2. B. Braun (Germany)
  3. Centre de Recherche Clinique at the Geneva University Hospitals
  4. European Commission (CHAMP network)
  5. European Commission (MOSAR network)
  6. European Commission (SATURN network)
  7. European Commission (AIDA network)
  8. European Commission (R-Gnosis network)
  9. European Commission (Rapp-ID network)
  10. European Commission (COMBACTE network)
  11. AstraZeneca
  12. Basile Pharmaceutica Ltd.
  13. Cempra Pharmaceuticals Inc.
  14. Da Volterra
  15. Durata Therapeutics Inc.
  16. Intercell AG
  17. Johnson Johnson Inc.
  18. Merck Co. Inc.
  19. Proteologics Ltd.
  20. Rib-X Pharmaceuticals
  21. European Commission FP7 SATURN [241796]
  22. European Commission FP7 AIDA [278348]
  23. European Commission FP7 R-GNOSIS [282512]

Ask authors/readers for more resources

Bacterial resistance to antibiotics is a growing clinical problem and public health threat. Antibiotic use is a known risk factor for the emergence of antibiotic resistance, but demonstrating the causal link between antibiotic use and resistance is challenging. This review describes different study designs for assessing the association between antibiotic use and resistance and discusses strengths and limitations of each. Approaches to measuring antibiotic use and antibiotic resistance are presented. Important methodological issues such as confounding, establishing temporality, and control group selection are examined.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available